Trial Information

Fractionated Stereotactic Radiotherapy in Patients With Acromegaly. Single Centre Experience

An audit was done on 34 patients with acromegaly (consecutive cohorte) treated with
fractionated stereotactic radiotherapy in Rigshospitalet/National University Hospital,
Copenhagen, Denmark. All patients had MR control regularly to monitor tunour control, and
biochemical control assessed by growth hormone measurements during an oral glucose tolerance
test. Furthermore all other pituitary axes were tested for sufficiency and concomitant
medication likewise registered. The 7 year interim analysis demonstrated an acceptable
tumour control and biochemical remission profile, and most patient had subsequent withdrawal
of somatostatin analogue- and growth hormone receptor antagonis therapy. The observational
study will continue with a new update in approx 2 years